Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Sunesis Pharmaceuticals (SNSS) Share Price

News stories about Sunesis Pharmaceuticals (NASDAQ:SNSS) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.1071945429524 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Trading Signals in Review For Sunesis Pharmaceuticals Inc (SNSS) – Bulletin News (orobulletin.com)
Investors Are Circling Sunesis Pharmaceuticals Inc (SNSS), What Do the Numbers Tell Us? – Evergreen Caller (evergreencaller.com)
Sunesis Pharmaceuticals Inc (SNSS) Moving -3.15% in Session – Stock Press Daily (stockpressdaily.com)
Proteon Therapeutics, Inc. (PRTO) is at $1.35 per share and Sunesis … – Stocks Gallery (stocksgallery.com)
Boom or Bust? Is there any value in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)? – FLBC News (flbcnews.com)

Sunesis Pharmaceuticals (NASDAQ:SNSS) traded down 0.92% during midday trading on Friday, hitting $2.15. 31,496 shares of the company traded hands. The stock’s 50-day moving average is $2.52 and its 200-day moving average is $3.36. Sunesis Pharmaceuticals has a 12-month low of $2.14 and a 12-month high of $6.30. The firm’s market capitalization is $50.55 million.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.35. During the same quarter last year, the company earned ($0.12) EPS. Analysts anticipate that Sunesis Pharmaceuticals will post ($1.61) EPS for the current fiscal year.

Several equities research analysts recently issued reports on SNSS shares. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 2nd. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research note on Thursday, May 11th.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by [[site]] and is the property of of [[site]]. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at [[permalink]].

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).